Evidence map›Paper›PMID 29101331›Full record

ArticleScientific reports2017

Conventional and unconventional secretory proteins expressed with silkworm bombyxin signal peptide display functional fidelity.

Sungjo Park, D Kent Arrell, Santiago Reyes, Enoch Y Park, Andre Terzic

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Sungjo ParkCenter for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
D Kent ArrellCenter for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Santiago ReyesCenter for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Enoch Y ParkLaboratory of Biotechnology, Graduate School of Science and Technology, Shizuoka University, Shizuoka, Japan.ORCID 0000-0002-7840-1424
Andre TerzicCenter for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA. terzic.andre@mayo.edu.
Mayo Clinic · USShizuoka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growth factors are signaling molecules which orchestrate cell growth, proliferation and differentiation. The majority are secreted proteins, exported through the classical endoplasmic reticulum (ER)/Golgi-dependent pathway, but a few are released by unconventional ER/Golgi-independent means. Human fibroblast growth factor 2 (FGF2) and insulin-like growth factor 1 (IGF1), are canonical prototypes secreted by the unconventional and conventional pathway, respectively. We herein examined whether expression of these two growth factors in the Bombyx mori nucleopolyhedrovirus (BmNPV)-based silkworm expression system with its innate signal peptide, bombyxin, secures structural homogeneity at the signal peptide cleavage site regardless of the native secretory route. Proteomic analysis mapped structural microheterogeneity of signal peptide cleavage at the amino terminus of FGF2, whereas IGF1 displayed homogeneous amino-terminal cleavage with complete removal of the bombyxin signal peptide. A cell proliferation assay revealed potent functional activity of both FGF2 and IGF1, suggesting that FGF2 amino-terminal microheterogeneity does not alter mitogenic activity. These findings demonstrate that the occurrence of amino-terminal structural homogeneity may be associated with the original secretion mechanism of a particular growth factor. Furthermore, our results highlight the bombyxin signal peptide as a reliable secretion sequence applicable to mass production of functionally active secretory proteins in a silkworm-based expression platform.

Indexed as

AnimalsAnimals, Genetically ModifiedBombyxCell ProliferationFibroblast Growth Factor 2HumansInsulin-Like Growth Factor IMiceNeuropeptidesNIH 3T3 CellsProteomeProteomicsRecombinant ProteinsbombyxinsFibroblast Growth Factor 2IGF1 protein, humanInsulin-Like Growth Factor INeuropeptidesProteomeRecombinant Proteins

Identifiers

PMID29101331
PMCPMC5670176
OpenAlexW2767035510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.